Jaeger U*
Medizinische Universität Wien
H-index: 95
Europe-Austria
Top articles of Jaeger U*
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. | Blood Advances | Marit Jalink Chaja F Jacobs Jahanzaib Khwaja Dorothea Evers Coty Bruggeman | 2024/3/22 |
Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study | International Journal of Hematology | Jun Takizawa Ritsuro Suzuki Koji Izutsu Toru Kiguchi Hideki Asaoku | 2024/3/16 |
A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells | Frontiers in Immunology | Mortimer Svec Sarah Dötsch Linda Warmuth Manuel Trebo Simon Fräßle | 2024/1/11 |
Phase II Single-Arm Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)-Final Results of the AGMT NHL15B … | Frontiers in Hematology | Ulrich Jaeger Alexander Egle Ingrid Simonitsch-Klupp Sonja Heibl Peter Neumeister | 2024/3/28 |
Affective temperament, fatigue, and pain in cancer patients | Journal of Affective Disorders | Matthias Knefel Elisabeth L Zeilinger Andreas Erfurth Simone Lubowitzki Otto Lesch | 2023 |
Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells | Blood | Rakesh Awasthi Edward Waldron Stephan Grupp Michael A Pulsipher Peter Bader | 2023/11/28 |
The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma | Frontiers in Immunology | Nina Worel Katharina Grabmeier-Pfistershammer Bernhard Kratzer Martina Schlager Andreas Tanzmann | 2023/1/9 |
S201: Final 7-year follow up and retreatment substudy analysis of murano: venetoclax-rituximab (venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R … | HemaSphere | Arnon Kater Rosemary Harrup Thomas J Kipps Barbara Eichhorst Carolyn J Owen | 2023/8/1 |
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) | Hematological Oncology | AP Kater R Harrup TJ Kipps B Eichhorst CJ Owen | 2023/6 |
Risk as a pattern over time: Delineation of time‐dependent risk factors in biological, psychological, and social variables in cancer patients | Cancer | Matthias Knefel Elisabeth L Zeilinger Simone Lubowitzki Katharina Krammer Matthias Unseld | 2023 |
TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma | Blood | Franck Morschhauser Saurabh Dahiya M Lia Palomba Alejandro Martin Garcia-Sancho Juan Luis Reguera | 2023/11/28 |
First-line venetoclax combinations in chronic lymphocytic leukemia | New England Journal of Medicine | Barbara Eichhorst Carsten U Niemann Arnon P Kater Moritz Fürstenau Julia Von Tresckow | 2023/5/11 |
CT-526 Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or … | Clinical Lymphoma Myeloma and Leukemia | Nirav N Shah Ian Flinn Mi Kwon Ulrich Jäger Javier Briones | 2023/9/1 |
Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a … | Blood | Richard Greil Petra Obrtlikova Lukas Smolej Tomas Kozak Michael Steurer | 2014/12/6 |
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study | Blood Advances | Adam J Olszewski Tycel J Phillips Marc S Hoffmann Philippe Armand Tae Min Kim | 2023/10/24 |
Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial | Blood | Lukas Kazianka Tea Pemovska Johannes Rohrbeck Christoph Kornauth Alexander Pichler | 2023/11/28 |
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS: H) version 1.0 | Annals of Oncology | B Kiesewetter U Dafni EGE de Vries Jorge Barriuso G Curigliano | 2023/9/1 |
Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: Phase 1b PORTIA study results | Blood Advances | Ulrich Jaeger Nina Worel Joseph P McGuirk Peter A Riedell Isabelle Fleury | 2023/6/13 |
A RANDOMIZED PHASE II STUDY OF MB‐CART2019. 1 COMPARED TO STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR ASCT–DALY 2‐EU TRIAL | Hematological Oncology | P Borchmann P Vandenberghe A Urbano‐Ispizua C Haiuon L Griškevicius | 2023/6 |
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations | Kai Rejeski Marion Subklewe Mahmoud Aljurf Emmanuel Bachy Adriana Balduzzi | 2023/9/7 |
